In financial markets, there are times when a single government decision can reveal more about the market than any analyst could write. One of those days was Tuesday, April 6. The Centers for Medicare and Medicaid Services finalized its 2027 Medicare Advantage payment rates at an average increase of 2.48% following months of mounting fear throughout the managed care industry—months of declining stock prices, rising medical costs, and a January rate proposal that felt like a door closing. UnitedHealth Group saw an almost 8% increase in after-hours trading in a matter of hours. Humana saw an 11% increase. The numbers moved quickly and significantly, and they revealed a narrative that had been told in the opposite direction for the previous 12 months.
It helps to realize how awful the previous year had been in order to comprehend why those moves feel important. Prior to this announcement, UnitedHealth’s stock had dropped 46.4% in the previous 12 months. Humana had experienced a 28.3% decline. Centene saw a 42.3% decline. Over the same period, the S&P 500 had increased 33.9%, primarily due to the AI trade, which diverted capital from defensive industries like healthcare and into technology companies that seemed, at least from a market perspective, more exciting. Instead of growing, investors were now managing down health insurers. If you were holding the stocks, the difference between these companies’ current positions and the state of the market as a whole was so stark that it felt personal.
| Topic | Details |
|---|---|
| Company | UnitedHealth Group (UNH) — largest Medicare Advantage insurer in the United States; part of a trio with Humana and CVS Health covering nearly 60% of all Medicare Advantage enrollees |
| Medicare Advantage Program | Serves approximately 35 million beneficiaries across the U.S.; a taxpayer-financed alternative to traditional Medicare administered through private insurers |
| 2027 Finalized Rate Increase | 2.48% average increase — finalized by CMS on April 6, 2026; sharply higher than the 0.09% proposed in January 2026 |
| Estimated Additional Revenue | $13 billion in additional payments projected for Medicare Advantage insurers in 2027, per CMS estimates |
| Stock Reaction (After-Hours) | UNH +7.8% · Humana (HUM) +11.1% · Centene (CNC) +4.3% — all posting gains within hours of the CMS announcement |
| 12-Month Stock Performance (Prior) | UNH fell 46.4% · HUM dropped 28.3% · CNC declined 42.3% — against an S&P 500 gain of 33.9% over the same period |
| January 2026 Proposal | CMS initially proposed a near-flat 0.09% rate increase — triggering sharp selloffs and raising industry fears of sustained margin compression |
| Key Policy Change | Trump administration scrapped a proposed risk adjustment model update that would have used more current data — preserving billions in existing insurer payments |
| DOJ Overhang | The Department of Justice opened a civil fraud investigation into UnitedHealth’s Medicare billing practices in February 2025, examining how diagnoses triggering extra payments are recorded |
| Prior Year Comparison | 2026 Medicare Advantage rate was finalized at 5.06% — itself revised upward from an initial 2.2% proposal, setting a precedent for CMS landing higher than its opening position |
The fear was solidified by the January proposal. CMS proposed a rate increase of 0.09%, which was so close to zero that it was practically identical to flat. A flat reimbursement rate was not neutral news for companies already dealing with higher-than-expected medical utilization, rising claims costs, and the general pressure of an aging enrollment base using healthcare more aggressively than actuarial models had predicted. It was a warning that the calculations might not be accurate for some time. Managed care stocks fell through February and March as a result of investors reading it that way and making the necessary adjustments.
Then April came, and CMS relocated. It’s important to be realistic about the fact that the finalized 2.48% increase won’t address every structural issue facing the Medicare Advantage sector. The trends of rising utilization have not reversed. The inflation of medical costs has persisted. No matter what CMS does with reimbursement rates, the Department of Justice’s civil fraud investigation into UnitedHealth’s Medicare billing practices remains open. It looks at how the company records diagnoses that result in additional payments. Some investors seem to have applauded the rate change with a sense of relief that marginally outweighed the real improvement in fundamentals. However, the finalized rate does significantly alter the math at the margin, which is where these businesses thrive or fail.
This announcement also included a structural policy change that may become more significant in the future but received less attention than the headline figure. A proposed update to the risk adjustment model, which would have calibrated payments using more recent patient data, was shelved by the Trump administration. That sounds confusing. There are no dollar implications.
Maintaining the previous model protects insurers’ billions of dollars in current payment flows, preventing a methodology change from adding to already-compressed margins. The administration’s decision to reverse the revised model was, by any reasonable interpretation, a major victory for UnitedHealth, Humana, CVS, and the other major Medicare Advantage operators, as industry groups had vigorously lobbied against it. It’s still unclear if that choice represents a long-term course for policy or if it was merely a political pact that might be changed in the future.
Here, the larger context is important. About 35 million Americans are covered by Medicare Advantage. It is one of Humana’s most important business lines, the biggest for UnitedHealth, and a significant source of income for CVS Health’s Aetna division. Together, those three businesses account for nearly 60% of all program participants. Network negotiations with hospitals and physician groups, quarterly earnings, and benefit design decisions for the upcoming year are all affected when CMS modifies the rates it pays these businesses. The $13 billion in extra payments that CMS anticipates for 2027 do not simply disappear into corporate balance sheets. It influences the features of plans, the appearance of premiums, and the experiences seniors have when attempting to utilize their coverage.
In a sector that had been consistently red for the majority of the previous year, watching the after-hours reaction on Tuesday with screens illuminating with green numbers felt more like real relief than conjecture. Those who keep a close eye on these companies are aware of how bad things got starting in mid-2025: not just stock chart underperformance, but also earnings calls where executives used cautious language to explain cost pressures that were outpacing models and guidance revisions delivered with the measured tone of companies trying not to alarm anyone. That stretch is not eliminated by the finalized rate of 2.48%. However, it closes a chapter of acute uncertainty that the January proposal had opened, and that distinction carries significant weight for an industry that had been trading more like it was in a crisis than a brief rough patch.